Loading...

Orville Kolterman

Title(s)Associate Physician, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #0835
La Jolla CA 92093
Phone8/5-34--5463
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    DIABETES CONTROL AND COMPLICATIONS TRIAL
    NIH/NIDDK U01DK037828Jul 23, 1986 - Jun 30, 1994
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care. 2020 07; 8(1). Perraudeau F, McMurdie P, Bullard J, Cheng A, Cutcliffe C, Deo A, Eid J, Gines J, Iyer M, Justice N, Loo WT, Nemchek M, Schicklberger M, Souza M, Stoneburner B, Tyagi S, Kolterman O. PMID: 32675291.
      View in: PubMed   Mentions:
    2. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. J Hepatol. 2020 Apr; 72(4):613-626. Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC. PMID: 31697972.
      View in: PubMed   Mentions: 6     Fields:    
    3. Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657-664. Diabetes Care. 2019 08; 42(8):e137. Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM. PMID: 31332032.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care. 2019 04; 42(4):657-664. Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM. PMID: 30728218.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    5. Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters. Obesity (Silver Spring). 2019 01; 27(1):59-67. Zemel MB, Kolterman O, Rinella M, Vuppalanchi R, Flores O, Barritt AS, Siddiqui M, Chalasani N. PMID: 30569637.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    6. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018 06; 47(12):1639-1651. Chalasani N, Vuppalanchi R, Rinella M, Middleton MS, Siddiqui MS, Barritt AS, Kolterman O, Flores O, Alonso C, Iruarrizaga-Lejarreta M, Gil-Redondo R, Sirlin CB, Zemel MB. PMID: 29696666.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    7. Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes. Diabetes Obes Metab. 2015 Sep; 17(9):904-7. Riddle MC, Yuen KC, de Bruin TW, Herrmann K, Xu J, Öhman P, Kolterman OG. PMID: 26040429.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    8. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes. 2015; 8:241-53. MacConell L, Gurney K, Malloy J, Zhou M, Kolterman O. PMID: 26056482.
      View in: PubMed   Mentions:
    9. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes. 2014 May; 63(5):1748-62. Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, Li SM, Cleary P, Riggs A, Harlan DM, Lorenzi G, Kolterman O, Sun W, Lachin JM, Natarajan R. PMID: 24458354.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    10. In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes. Diabetes Technol Ther. 2013 Oct; 15(10):802-9. Micheletto F, Dalla Man C, Kolterman O, Chiquette E, Herrmann K, Schirra J, Kovatchev B, Cobelli C. PMID: 23865841.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    11. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med. 2013 May; 125(3):136-44. Herrmann K, Frias JP, Edelman SV, Lutz K, Shan K, Chen S, Maggs D, Kolterman OG. PMID: 23748514.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    12. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007 Nov; 30(11):2794-9. Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O. PMID: 17698615.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    13. Pharmacometrics and the transition to model-based development. Clin Pharmacol Ther. 2007 Aug; 82(2):137-42. Grasela TH, Dement CW, Kolterman OG, Fineman MS, Grasela DM, Honig P, Antal EJ, Bjornsson TD, Loh E. PMID: 17632539.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    14. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab. 2007 May; 3(5):E1; discussion E2. Edelman SV, Garg S, Kolterman OG. PMID: 17452962.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2007 Feb; 30(2):210-6. Marrero DG, Crean J, Zhang B, Kellmeyer T, Gloster M, Herrmann K, Rubin R, Fineberg N, Kolterman O. PMID: 17259483.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    16. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct; 29(10):2189-95. Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O. PMID: 17003291.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    17. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag. 2006; 2(1):69-77. Schnabel CA, Wintle M, Kolterman O. PMID: 17319471.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    18. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab. 2005 Sep; 7(5):504-16. Amiel SA, Heller SR, Macdonald IA, Schwartz SL, Klaff LJ, Ruggles JA, Weyer C, Kolterman OG, Maggs DG. PMID: 16050943.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    19. Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm. 2005 Apr 15; 62(8):816-22. Weyer C, Fineman MS, Strobel S, Shen L, Data J, Kolterman OG, Sylvestri MF. PMID: 15821274.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    20. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes. 2005 Apr; 113(4):199-204. Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, Kolterman OG, Weyer C. PMID: 15891954.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    21. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005 Jan 15; 62(2):173-81. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. PMID: 15700891.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCTClinical Trials
    22. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004 Nov; 21(11):1204-12. Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG. PMID: 15498087.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    23. Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism. 2004 Sep; 53(9):1227-32. Heise T, Heinemann L, Heller S, Weyer C, Wang Y, Strobel S, Kolterman O, Maggs D. PMID: 15334389.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    24. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004 Apr; 12(4):661-8. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C. PMID: 15090634.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    25. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev. 2004 Jan-Feb; 20(1):55-60. Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C. PMID: 14737746.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    26. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism. 2003 Dec; 52(12):1638-42. Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C. PMID: 14669170.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    27. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care. 2003 Nov; 26(11):3074-9. Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG. PMID: 14578242.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    28. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab. 2003 Nov; 5(6):408-14. Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, Kolterman O, Weyer C. PMID: 14617226.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    29. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003 Jul; 88(7):3082-9. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. PMID: 12843147.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansCTClinical Trials
    30. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003 Mar; 26(3):784-90. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG. PMID: 12610038.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    31. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003 Jan; 26(1):1-8. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR. PMID: 12502651.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    32. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002 Sep; 34(9):504-8. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. PMID: 12384827.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    33. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002 May; 51(5):636-41. Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG. PMID: 11979398.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    34. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002 Apr; 25(4):724-30. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG. PMID: 11919132.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    35. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002; 4(1):51-61. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG. PMID: 12017421.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    36. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001 Sep; 7(14):1353-73. Weyer C, Maggs DG, Young AA, Kolterman OG. PMID: 11472273.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimals
    37. Amylin innocent in essential hypertension? Diabetologia. 1999 Aug; 42(8):1029. Young A, Kolterman O, Hall J. PMID: 10491767.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    38. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism. 1999 Jul; 48(7):935-41. Nyholm B, Orskov L, Hove KY, Gravholt CH, Møller N, Alberti KG, Moyses C, Kolterman O, Schmitz O. PMID: 10421239.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    39. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care. 1998 Jun; 21(6):987-93. Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG. PMID: 9614619.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    40. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia. 1997 Nov; 40(11):1278-85. Thompson RG, Pearson L, Kolterman OG. PMID: 9389419.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    41. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med. 1997 Jul; 14(7):547-55. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG. PMID: 9223392.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    42. Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide. Diabet Med. 1997 Jun; 14 Suppl 2:S35-8. Kolterman OG. PMID: 9212328.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. Modulation of gastric emptying as a therapeutic approach to glycaemic control. Diabet Med. 1996 Sep; 13(9 Suppl 5):S34-8. Moyses C, Young A, Kolterman O. PMID: 8894469.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    44. Self-care behaviors in insulin-dependent diabetes: evaluative tools and their associations with glycemic control. J Pediatr Psychol. 1996 Aug; 21(4):467-82. Hanson CL, De Guire MJ, Schinkel AM, Kolterman OG, Goodman JP, Buckingham BA. PMID: 8863457.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    45. Effect of race and hypertension on plasma amylin concentrations. Hypertension. 1996 Jun; 27(6):1273-6. Dimsdale JE, Kolterman O, Koda J, Nelesen R. PMID: 8641735.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    46. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia. 1996 Apr; 39(4):492-9. Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A. PMID: 8778001.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    47. Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J Clin Pharmacol. 1996 Jan; 36(1):13-24. Colburn WA, Gottlieb AB, Koda J, Kolterman OG. PMID: 8932539.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    48. Empirical validation for a family-centered model of care. Diabetes Care. 1995 Oct; 18(10):1347-56. Hanson CL, De Guire MJ, Schinkel AM, Kolterman OG. PMID: 8721936.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    49. Low-carbohydrate diet alters intracellular glucose metabolism but not overall glucose disposal in exercise-trained subjects. Metabolism. 1995 Oct; 44(10):1264-70. Cutler DL, Gray CG, Park SW, Hickman MG, Bell JM, Kolterman OG. PMID: 7476282.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    50. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care. 1995 Aug; 18(8):1179-82. Kolterman OG, Gottlieb A, Moyses C, Colburn W. PMID: 7587855.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    51. Elevated insulin, norepinephrine, and neuropeptide Y in hypertension. Am J Hypertens. 1990 Nov; 3(11):823-8. Solt VB, Brown MR, Kennedy B, Kolterman OG, Ziegler MG. PMID: 2261148.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    52. Correlation of in vivo and in vitro actions of insulin in obesity and noninsulin-dependent diabetes mellitus: role of the glucose transport system. Diabetes Metab Rev. 1988 Sep; 4(6):543-69. Garvey WT, Kolterman OG. PMID: 3065009.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    53. Day-long integrated serum insulin and C-peptide profiles in patients with NIDDM. Correlation with urinary C-peptide excretion. Diabetes. 1988 May; 37(5):590-9. Garvey WT, Olefsky JM, Rubenstein AH, Kolterman OG. PMID: 3282946.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    54. Decreased activation of skeletal muscle glycogen synthase by mixed-meal ingestion in NIDDM. Diabetes. 1988 Apr; 37(4):436-40. Wright KS, Beck-Nielsen H, Kolterman OG, Mandarino LJ. PMID: 2837418.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    55. Continuous subcutaneous insulin infusion in an obese insulin-resistant pregnant woman with type II diabetes: accelerated fetal growth and neonatal complications. Obstet Gynecol. 1987 Sep; 70(3 Pt 2):480-5. Moore TR, Hollingsworth DR, Kolterman O, Nager C. PMID: 3627609.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics. Metabolism. 1987 May; 36(5):409-15. Baron AD, Eckel RH, Schmeiser L, Kolterman OG. PMID: 3553848.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    57. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 1987 Mar; 36(3):274-83. Baron AD, Schaeffer L, Shragg P, Kolterman OG. PMID: 2879757.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    58. Metabolic consequence of two-week fructose feeding in diabetic subjects. Diabetes Care. 1986 Mar-Apr; 9(2):111-9. Crapo PA, Kolterman OG, Henry RR. PMID: 3516605.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    59. In vivo deactivation of proinsulin action on glucose disposal and hepatic glucose production in normal man. Diabetes. 1986 Mar; 35(3):311-7. Glauber HS, Revers RR, Henry R, Schmeiser L, Wallace P, Kolterman OG, Cohen RM, Rubenstein AH, Galloway JA, Frank BH. PMID: 3512341.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    60. Metabolic consequences of very-low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects. Diabetes. 1986 Feb; 35(2):155-64. Henry RR, Wiest-Kent TA, Scheaffer L, Kolterman OG, Olefsky JM. PMID: 3510922.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    61. Rates of noninsulin-mediated glucose uptake are elevated in type II diabetic subjects. J Clin Invest. 1985 Nov; 76(5):1782-8. Baron AD, Kolterman OG, Bell J, Mandarino LJ, Olefsky JM. PMID: 2865274.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    62. Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus. Am J Med. 1985 Sep 20; 79(3B):23-33. Kolterman OG. PMID: 3931459.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    63. The metabolic clearance of insulin and the feedback inhibition of insulin secretion are altered with aging. Diabetes. 1985 Mar; 34(3):275-80. Fink RI, Revers RR, Kolterman OG, Olefsky JM. PMID: 3882495.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    64. Modulation of insulin secretion by insulin and glucose in type II diabetes mellitus. J Clin Endocrinol Metab. 1985 Mar; 60(3):559-68. Garvey WT, Revers RR, Kolterman OG, Rubenstein AH, Olefsky JM. PMID: 3882736.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    65. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985 Mar; 34(3):222-34. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. PMID: 3882489.
      View in: PubMed   Mentions: 112     Fields:    Translation:Humans
    66. Insulin resistance in non-insulin dependent (type II) and insulin dependent (type I) diabetes mellitus. Adv Exp Med Biol. 1985; 189:176-205. Olefsky JM, Revers RR, Prince M, Henry RR, Garvey WT, Scarlett JA, Kolterman OG. PMID: 3898763.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    67. The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes. 1984 Aug; 33(8):762-70. Revers RR, Henry R, Schmeiser L, Kolterman O, Cohen R, Bergenstal R, Polonsky K, Jaspan J, Rubenstein A, Frank B. PMID: 6378699.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    68. The metabolic effects of biosynthetic human proinsulin in individuals with type I diabetes. J Clin Endocrinol Metab. 1984 Jun; 58(6):973-9. Bergenstal RM, Cohen RM, Lever E, Polonsky K, Jaspan J, Blix PM, Revers R, Olefsky JM, Kolterman O, Steiner K. PMID: 6373814.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    69. Biosynthetic human insulin and proinsulin have additive but not synergistic effects on total body glucose disposal. J Clin Endocrinol Metab. 1984 Jun; 58(6):1094-8. Revers RR, Henry R, Schmeiser L, Kolterman O, Cohen R, Rubenstein A, Frank B, Galloway J, Olefsky JM. PMID: 6373809.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    70. The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes. Diabetes Care. 1984 May-Jun; 7 Suppl 1:81-8. Kolterman OG, Olefsky JM. PMID: 6376033.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    71. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984 Apr; 33(4):346-54. Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM. PMID: 6423429.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    72. Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J Clin Invest. 1984 Mar; 73(3):664-72. Revers RR, Fink R, Griffin J, Olefsky JM, Kolterman OG. PMID: 6368585.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    73. Lack of in vivo insulin resistance in controlled insulin-dependent, type I, diabetic patients. J Clin Endocrinol Metab. 1984 Feb; 58(2):353-8. Revers RR, Kolterman OG, Scarlett JA, Gray RS, Olefsky JM. PMID: 6363437.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    74. Insulin receptors in isolated human adipocytes. Characterization by photoaffinity labeling and evidence for internalization and cellular processing. J Clin Invest. 1983 Dec; 72(6):1958-70. Berhanu P, Kolterman OG, Baron A, Tsai P, Olefsky JM, Brandenburg D. PMID: 6358259.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    75. Relationship between serum glucose level and the metabolic clearance rate of glucose in non-insulin-dependent diabetes mellitus. Diabetes. 1983 Jul; 32(7):627-32. Revers RR, Kolterman OG, Olefsky JM. PMID: 6345242.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    76. Insulin treatment reverses the postreceptor defect in adipocyte 3-O-methylglucose transport in type II diabetes mellitus. J Clin Endocrinol Metab. 1983 Jun; 56(6):1195-201. Scarlett JA, Kolterman OG, Ciaraldi TP, Kao M, Olefsky JM. PMID: 6341390.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    77. Mechanisms of insulin resistance in aging. J Clin Invest. 1983 Jun; 71(6):1523-35. Fink RI, Kolterman OG, Griffin J, Olefsky JM. PMID: 6345584.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCells
    78. Insulin resistance in noninsulin-dependent diabetes mellitus: impact of sulfonylurea agents in vivo and in vitro. Am J Med. 1983 Jan 17; 74(1A):82-101. Kolterman OG, Prince MJ, Olefsky JM. PMID: 6401923.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    79. Role of glucose transport in the postreceptor defect of non-insulin-dependent diabetes mellitus. Diabetes. 1982 Nov; 31(11):1016-22. Ciaraldi TP, Kolterman OG, Scarlett JA, Kao M, Olefsky JM. PMID: 6757010.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    80. The effects of oral fructose, sucrose, and glucose in subjects with reactive hypoglycemia. Diabetes Care. 1982 Sep-Oct; 5(5):512-7. Crapo PA, Scarlett JA, Kolterman OG, Sanders LR, Hofeldt FD, Olefsky JM. PMID: 6765227.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    81. Comparison of the metabolic responses to fructose and sucrose sweetened foods. Am J Clin Nutr. 1982 Aug; 36(2):256-61. Crapo PA, Scarlett JA, Kolterman OG. PMID: 7048890.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    82. Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus. Am J Physiol. 1982 Jul; 243(1):E15-30. Olefsky JM, Kolterman OG, Scarlett JA. PMID: 7046470.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    83. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care. 1982 Jul-Aug; 5(4):353-63. Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG. PMID: 6759075.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    84. Insulin resistance and diabetes due to a genetic defect in insulin receptors. J Clin Endocrinol Metab. 1982 Jul; 55(1):123-31. Scarlett JA, Kolterman OG, Moore P, Saekow M, Insel J, Griffin J, Mako M, Rubenstein AH, Olefsky JM. PMID: 7042734.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    85. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Invest. 1981 Oct; 68(4):957-69. Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J, Scarlett JA, Olefsky JM. PMID: 7287908.
      View in: PubMed   Mentions: 134     Fields:    Translation:Humans
    86. Comparison of serum glucose, insulin, and glucagon responses to different types of complex carbohydrate in noninsulin-dependent diabetic patients. Am J Clin Nutr. 1981 Feb; 34(2):184-90. Crapo PA, Insel J, Sperling M, Kolterman OG. PMID: 7010982.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCTClinical Trials
    87. A defect in cell-mediated immune function in insulin-resistant diabetic and obese subjects. J Lab Clin Med. 1980 Sep; 96(3):535-43. Kolterman OG, Olefsky JM, Kurahara C, Taylor K. PMID: 6995542.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    88. Effects of oral fructose in normal, diabetic, and impaired glucose tolerance subjects. Diabetes Care. 1980 Sep-Oct; 3(5):575-82. Crapo PA, Kolterman OG, Olefsky JM. PMID: 7002511.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    89. Postprandial hormonal responses to different types of complex carbohydrate in individuals with impaired glucose tolerance. Am J Clin Nutr. 1980 Aug; 33(8):1723-8. Crapo PA, Kolterman OG, Waldeck N, Reaven GM, Olefsky JM. PMID: 6996472.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCTClinical Trials
    90. Short-term regulation of insulin receptor affinity in man. Diabetes. 1980 Feb; 29(2):132-9. Insel JR, Kolterman OG, Saekow M, Olefsky JM. PMID: 6986298.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    91. Effect of a high carbohydrate diet on insulin binding to adipocytes and on insulin action in vivo in man. Diabetes. 1979 Aug; 28(8):731-6. Kolterman OG, Greenfield M, Reaven GM, Saekow M, Olefsky JM. PMID: 446930.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    92. The effects of acute and chronic starvation on insulin binding to isolated human adipocytes. J Clin Endocrinol Metab. 1979 May; 48(5):836-42. Kolterman OG, Saekow M, Olefsky JM. PMID: 429529.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    93. The effect of ten days of fasting on various aspects of carbohydrate metabolism in obese diabetic subjects with significant fasting hyperglycemia. Metabolism. 1978 Dec; 27(12 Suppl 2):1839-52. Greenfield M, Kolterman O, Olefsky JM, Reaven GM. PMID: 723636.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    Orville's Networks
    Concepts (246)
    Derived automatically from this person's publications.
    _
    Co-Authors (5)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _